ADAPTIVE BIOTECHNOLOGIES COR's ticker is ADPT and the CUSIP is 00650F109. A total of 190 filers reported holding ADAPTIVE BIOTECHNOLOGIES COR in Q3 2023. The put-call ratio across all filers is 0.86 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $3,918,915 | -20.8% | 719,067 | -2.5% | 0.63% | -11.0% |
| Q2 2023 | $4,949,222 | -32.0% | 737,589 | -10.5% | 0.71% | -35.7% |
| Q1 2023 | $7,275,796 | -5.9% | 823,986 | -18.6% | 1.10% | -12.9% |
| Q4 2022 | $7,734,744 | +31.1% | 1,012,401 | +22.2% | 1.27% | +25.0% |
| Q3 2022 | $5,898,000 | +115.2% | 828,302 | +144.5% | 1.01% | +116.7% |
| Q2 2022 | $2,741,000 | -41.8% | 338,789 | -0.2% | 0.47% | -22.3% |
| Q1 2022 | $4,713,000 | -14.4% | 339,541 | +73.0% | 0.60% | +3.6% |
| Q4 2021 | $5,508,000 | -18.0% | 196,302 | -0.6% | 0.58% | -16.5% |
| Q3 2021 | $6,713,000 | -17.7% | 197,492 | -1.1% | 0.70% | -14.9% |
| Q2 2021 | $8,160,000 | +29.1% | 199,697 | +27.2% | 0.82% | +36.6% |
| Q1 2021 | $6,319,000 | -27.3% | 156,961 | +6.8% | 0.60% | -34.9% |
| Q4 2020 | $8,690,000 | +26.4% | 146,968 | +4.0% | 0.92% | -8.4% |
| Q3 2020 | $6,874,000 | +22.5% | 141,362 | +21.8% | 1.00% | +11.8% |
| Q2 2020 | $5,613,000 | – | 116,029 | – | 0.90% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Blue Water Life Science Advisors, LP | 2,377,665 | $12,958,274 | 12.23% |
| Eagle Health Investments LP | 1,214,860 | $6,620,987 | 1.46% |
| Matrix Capital Management Company, LP | 11,572,590 | $63,070,616 | 0.76% |
| Aristotle Atlantic Partners, LLC | 3,058,206 | $16,667,223 | 0.67% |
| VIKING GLOBAL INVESTORS LP | 29,993,708 | $163,465,709 | 0.66% |
| Pier Capital, LLC | 719,067 | $3,918,915 | 0.63% |
| DDD Partners, LLC | 783,697 | $3,385,571 | 0.49% |
| ARK Investment Management | 11,509,308 | $62,725,728 | 0.48% |
| Nikko Asset Management Americas, Inc. | 6,570,939 | $35,680,199 | 0.43% |
| Triatomic Management LP | 102,889 | $560,745 | 0.39% |